Stress response to radiation sensitizes immunologically nonresponsive tumors to cytotoxic T‐
lymphocyte‐associated protein 4 (CTLA‐4) therapy. The combination of radiotherapy (RT) …

T cell–engaging bispecific antibodies (TCB) are highly potent therapeutics that can recruit
and activate cytotoxic T cells to stimulate an antitumor immune response. However, the …

Immunotherapy has emerged as a promising strategy for cancer treatment, in which durable
immune responses were generated in patients with malignant tumors. In the past decade …

Oral squamous cell carcinoma (OSCC) accounts for nearly 90% of oral cavity malignancies.
However, despite significant advances in the last four decades, little improvement has been …

Immune checkpoint blockade (ICB) therapy is a revolutionary approach to treat cancers, but
still have limited clinical applications. Accumulating evidence pinpoints the …

Colorectal cancer (CRC) is the third most diagnosed malignancy and the second leading
cause of cancer-related deaths worldwide. Locally advanced and metastatic disease exhibit …

Pleural and peritoneal metastasis accompanied by malignant pleural effusion (MPE) or
malignant ascites (MA) is frequent in patients with advanced solid tumors that originate from …

Immunotherapy has emerged as a promising approach to combat immunosuppressive
tumor microenvironment (TME) for improved cancer treatment. FDA approval for the clinical …

Abstract Immunity-related GTPase M (IRGM), an Interferon-inducible protein, functions as a
pivotal immunoregulator in multiple autoimmune diseases and infection. However, the role …

Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and is the
third leading cause of tumor-related mortality worldwide. In recent years, the emergency of …